PMV Pharmaceuticals published Phase I data in the New England Journal of Medicine showing clinical activity for rezatapopt, a small molecule designed to reactivate mutant p53 in tumors bearing the TP53 Y220C mutation. Across 77 heavily pretreated patients, the compound was generally well tolerated and produced objective responses in multiple tumor types, supporting a registrational Phase II strategy. Researchers reported biomarker data consistent with selective binding to the Y220C pocket and restoration of wild‑type p53 function. PMV said the results validate the approach and plan an NDA submission pathway for platinum‑resistant/refractory ovarian cancer, targeting a filing in 2027 for that indication.